9715 KEY WEST AVENUE, ROCKVILLE, MD
Merger Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Employee Meeting
Announces Second Quarter 2026 Financial Results
Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale
To Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals Annual Meeting Results; Directors Elected
Milestone Payment Achieved Under CVR Agreement - $33.4 Million Due
Announces First Quarter 2026 Financial Results
Q2
Q1
FY 2025
Q3
FY 2023
Prospectus Filed Pursuant to Rule 425
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Third Party
S-8 POS